Drugs approved for pain also reduce bone cancer growth, Hopkins-led pre-clinical study finds

NCCN publishes guidelines for pediatric Ewing sarcoma

The National Comprehensive Cancer Network published the first-ever edition of NCCN Clinical Practice Guidelines in Oncology for Pediatric Bone Sarcoma.

October 09, 2026

Vol.52 No.37

Clinical Roundup

Cigarette smoke may prime lung stem cells for different types of lung cancer, Hopkins study finds

Chronic exposure to cigarette smoke may reprogram different populations of lung stem cells, which maintain and repair lung tissue, in ways that make them vulnerable to specific cancer-causing gene alterations and ultimately helps determine the type of lung cancer that develops.

October 09, 2026

Vol.52 No.37

Clinical Roundup

Johns Hopkins investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer

Immune cells can reach head and neck tumors, but once there, many stop functioning. This helps explain why immunotherapy with immune checkpoint inhibitors—which have transformed treatment for some cancers—benefit only 17% to 23% of patients with head and neck squamous cell carcinoma.

October 02, 2026

Vol.52 No.36

Clinical Roundup

Blood test could guide future treatment in Ewing sarcoma, Dana-Farber study finds

A blood test may help doctors identify which patients with Ewing sarcoma are at greater risk of relapse, according to a study led by investigators at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and the Children’s Oncology Group. The findings lay the groundwork for more personalized treatment strategies in this rare cancer.

September 25, 2026

Vol.52 No.35

Clinical Roundup

OST-HER2-treated patients show statistically significant benefit in interim three-year OS analysis of phase IIb pulmonary metastatic osteosarcoma trial

OST-HER2-treated patients showed statistically significant benefit in an interim three-year overall survival data analysis when compared with a combined published historical control arm being used for regulatory interactions. The analysis is from the company’s phase IIb trial for the prevention or delay of recurrence in patients with fully resected, pulmonary metastatic osteosarcoma (the “Metastatic Osteosarcoma Program”).

September 18, 2026

Vol.52 No.34

Guest Editorial

From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma

In November 2022, I was 43 years old, healthy, active, and the founding CEO of the publicly traded tech company GitLab.

August 14, 2026

Vol.52 No.32

By Sid Sijbrandij

Drugs approved for pain also reduce bone cancer growth, Hopkins-led pre-clinical study finds

YOU MAY BE INTERESTED IN

NCCN publishes guidelines for pediatric Ewing sarcoma

Cigarette smoke may prime lung stem cells for different types of lung cancer, Hopkins study finds

Johns Hopkins investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer

Blood test could guide future treatment in Ewing sarcoma, Dana-Farber study finds

OST-HER2-treated patients show statistically significant benefit in interim three-year OS analysis of phase IIb pulmonary metastatic osteosarcoma trial

From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma

Renew today!

Subscriber content

Never miss an issue!

Login

Drugs approved for pain also reduce bone cancer growth, Hopkins-led pre-clinical study finds

YOU MAY BE INTERESTED IN

NCCN publishes guidelines for pediatric Ewing sarcoma

Cigarette smoke may prime lung stem cells for different types of lung cancer, Hopkins study finds

Johns Hopkins investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer

Blood test could guide future treatment in Ewing sarcoma, Dana-Farber study finds

OST-HER2-treated patients show statistically significant benefit in interim three-year OS analysis of phase IIb pulmonary metastatic osteosarcoma trial

From “default dead” to living the future of cancer careAs founding CEO of GitLab, I went “founder mode” on my osteosarcoma

Never miss an issue!

Login

From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma